Establishment Labs shares in focus after revenue beat and guidance raise, supported by Motiva and minimally invasive products.
Stock Earnings Results
May 6, 2026
Table of Contents
May 6, 2026
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported first-quarter 2026 revenue above expectations and raised its full-year guidance, supported by strong Motiva sales, minimally invasive product growth, margin expansion, and improved adjusted EBITDA.
Establishment Labs is a medical technology company focused on women’s health, breast aesthetics, reconstruction, and minimally invasive aesthetic products.
The company reported a loss of $0.40 per share, wider than estimates for a loss of $0.28, representing a negative 42.9% earnings surprise. Revenue came in at $59.88 million, above estimates of $57.49 million, with revenue increasing 44.7% year-over-year.
Establishment Labs reported total revenue of $59.9 million, up from $41.4 million in the prior-year period.
Motiva U.S. revenue increased to $19.6 million, compared with $6.2 million a year earlier, while minimally invasive revenue reached $9.1 million for the quarter.
The company raised its 2026 revenue guidance to $266.5 million to $268.5 million, up from its previous range of $264 million to $266 million.
It also raised expectations for its minimally invasive business, now expecting more than $35 million in 2026 revenue, up from prior guidance of $30 million.
Gross margin improved to 70.7%, compared with 67.2% in the year-ago period, driven mainly by geographic and channel mix.
Adjusted EBITDA improved to positive $1.2 million, compared with a loss of $12.1 million a year earlier, marking the company’s third consecutive quarter of positive adjusted EBITDA.
The company used $7.5 million in cash during the quarter, compared with $21.2 million in the prior-year period.
Establishment Labs ended the quarter with $68.1 million in cash and said it expects to become free cash flow positive in the second half of 2026.
Investors are likely to watch whether Establishment Labs can sustain U.S. Motiva growth while improving profitability.
The key areas are:
Establishment Labs’ quarter shows how medtech earnings can still carry a positive growth signal even when EPS misses.
The wider-than-expected loss is a weakness, but revenue growth, higher guidance, margin expansion, and positive adjusted EBITDA point to improving operating leverage.
Platforms like LevelFields track earnings releases alongside activist investor stake, layoffs, corporate events, and dividends, helping investors identify when a company’s earnings report includes multiple signals that can drive repricing.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE